Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 80

1.

Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker.

Pietrasz D, Pécuchet N, Garlan F, Didelot A, Dubreuil O, Doat S, Imbert-Bismut F, Karoui M, Vaillant JC, Taly V, Laurent-Puig P, Bachet JB.

Clin Cancer Res. 2017 Jan 1;23(1):116-123. doi: 10.1158/1078-0432.CCR-16-0806. Epub 2016 Dec 19.

PMID:
27993964
2.

High-Sensitivity Cardiac Troponin T: a Preanalytical Evaluation.

Michel M, Mestari F, Alkouri R, Atlan Grégory, Dever S, Devilliers C, Imbert-Bismut F, Bonnefont-Rousselot D, Monneret D.

Clin Lab. 2016;62(4):743-8.

PMID:
27215098
3.

Stability of Routine Biochemical Analytes in Whole Blood and Plasma From Lithium Heparin Gel Tubes During 6-hr Storage.

Monneret D, Godmer A, Le Guen R, Bravetti C, Emeraud C, Marteau A, Alkouri R, Mestari F, Dever S, Imbert-Bismut F, Bonnefont-Rousselot D.

J Clin Lab Anal. 2016 Sep;30(5):602-9. doi: 10.1002/jcla.21909. Epub 2016 Feb 18.

PMID:
26891785
4.

Comparison of a 10- vs. 15-min centrifugation time for chemical and immunochemical assays and impact on turnaround time in a hospital laboratory.

Monneret D, Corlouer C, Bigot J, Atlan G, Alkouri R, Mestari F, Dever S, Imbert-Bismut F, Bonnefont-Rousselot D.

Clin Chem Lab Med. 2016 Apr;54(4):e117-21. doi: 10.1515/cclm-2015-0664. No abstract available.

PMID:
26479346
5.

S100B protein concentration measurement according to two different immunoassays.

Feriel J, Adamo F, Monneret D, Trehel-Tursis V, Favard S, Tsé C, Puybasset L, Bonnefont-Rousselot D, Imbert-Bismut F.

Clin Chem Lab Med. 2015 Jun;53(7):e169-71. doi: 10.1515/cclm-2014-1090. No abstract available.

PMID:
25719325
6.

Hemolysis indexes for biochemical tests and immunoassays on Roche analyzers: determination of allowable interference limits according to different calculation methods.

Monneret D, Mestari F, Atlan G, Corlouer C, Ramani Z, Jaffre J, Dever S, Fressart V, Alkouri R, Lamari F, Devilliers C, Imbert-Bismut F, Bonnefont-Rousselot D.

Scand J Clin Lab Invest. 2015 Apr;75(2):162-9. doi: 10.3109/00365513.2014.993691. Epub 2015 Jan 22.

PMID:
25608598
7.

Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.

Perazzo H, Munteanu M, Ngo Y, Lebray P, Seurat N, Rutka F, Couteau M, Jacqueminet S, Giral P, Monneret D, Imbert-Bismut F, Ratziu V, Hartemann-Huertier A, Housset C, Poynard T; FLIP Consortium..

Aliment Pharmacol Ther. 2014 Nov;40(9):1081-93. doi: 10.1111/apt.12946. Epub 2014 Sep 3.

8.

Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".

Perazzo H, Pais R, Munteanu M, Ngo Y, Monneret D, Imbert-Bismut F, Moussalli J, Lebray P, Benhamou Y, Thabut D, Ratziu V, de Ledhingen V, Poynard T; FibroFrance Group.; EPIC3 Group..

Clin Res Hepatol Gastroenterol. 2014 Sep;38(4):432-9. doi: 10.1016/j.clinre.2014.04.006. Epub 2014 Jun 9.

PMID:
24924901
9.

Analytical comparison of the new point-of-care troponin T immunoassay on AQT90Flex® analyzer (Radiometer) and the high-sensitivity troponin T immunoassay on ModularE170® (Roche Diagnostics).

Monneret D, Abbes RA, Omarjee R, Devilliers C, Le Manach Y, Raux M, Coriat P, Imbert-Bismut F, Bonnefont-Rousselot D.

Clin Chem Lab Med. 2014 Dec;52(12):e279-82. doi: 10.1515/cclm-2014-0231. No abstract available.

PMID:
24914726
10.

Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.

Calin R, Guiguet M, Desire N, Imbert-Bismut F, Munteanu M, Poynard T, Valantin MA, Stitou H, Katlama C, Thibault V.

J Clin Virol. 2013 Oct;58(2):408-14. doi: 10.1016/j.jcv.2013.07.018. Epub 2013 Aug 6.

PMID:
23958588
11.

Small platelet microparticle levels are increased in pulmonary arterial hypertension.

Nadaud S, Poirier O, Girerd B, Blanc C, Montani D, Eyries M, Imbert-Bismut F, Pacheco A, Vigne J, Tregouet DA, Humbert M, Soubrier F.

Eur J Clin Invest. 2013 Jan;43(1):64-71. doi: 10.1111/eci.12018. Epub 2012 Nov 26.

PMID:
23176388
12.

Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort study.

M'Kada H, Perazzo H, Munteanu M, Ngo Y, Ramanujam N, Fautrel B, Imbert-Bismut F, Ratziu V, Schuppe-Koistinen I, Leblond V, Delattre JY, Samson Y, Caen OL, Bricaire F, Khayat D, Pierrot-Deseilligny C, Herson S, Amoura Z, Tilleul P, Deckmyn O, Coriat P, Delpech VN, Boulogne P, Bonnefont-Rousselot D, Poynard T; Drug Induced Liver Injury Groupe Hospitalier Pitié-Salpêtrière Group.; Safer and Faster Evidence-based Translation Consortium..

PLoS One. 2012;7(8):e42418. Epub 2012 Aug 14.

13.

Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab.

Geri G, Terrier B, Imbert-Bismut F, Saadoun D, Sène D, Poynard T, Cacoub P.

J Viral Hepat. 2012 Jul;19(7):497-500. doi: 10.1111/j.1365-2893.2011.01571.x. Epub 2012 Jan 3.

PMID:
22676362
14.

Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

Poynard T, Munteanu M, Deckmyn O, Ngo Y, Drane F, Castille JM, Housset C, Ratziu V, Imbert-Bismut F.

J Hepatol. 2012 Sep;57(3):541-8. doi: 10.1016/j.jhep.2012.04.025. Epub 2012 May 18.

PMID:
22612998
15.

What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI).

M'Kada H, Munteanu M, Perazzo H, Ngo Y, Ramanujam N, Imbert-Bismut F, Ratziu V, Bonnefont-Rousselot D, Souberbielle B, Schuppe-Koistinen I, Poynard T; DILI group of the SAFE-T consortium..

Regul Toxicol Pharmacol. 2011 Aug;60(3):290-5. doi: 10.1016/j.yrtph.2011.04.002. Epub 2011 Apr 24.

PMID:
21539883
16.

Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.

Poynard T, Munteanu M, Deckmyn O, Ngo Y, Drane F, Messous D, Castille JM, Housset C, Ratziu V, Imbert-Bismut F.

BMC Gastroenterol. 2011 Apr 14;11:39. doi: 10.1186/1471-230X-11-39.

17.

ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure.

Poynard T, Munteanu M, Ngo Y, Castera L, Halfon P, Ratziu V, Imbert-Bismut F, Thabut D, Bourliere M, Cacoub P, Messous D, de Ledinghen V.

Gastroenterol Clin Biol. 2010 Aug-Sep;34(6-7):388-96. doi: 10.1016/j.gcb.2010.05.001. Epub 2010 Jul 2.

18.

Evaluation of FibroTest inter-laboratory variations requires standardization on analytical systems and should not be mixed with underpowered histological validation.

Munteanu M, Imbert-Bismut F, Housset C, Messous D, Fellahi S, Poynard T.

Clin Chim Acta. 2010 Feb;411(3-4):292-3. doi: 10.1016/j.cca.2009.11.015. Epub 2009 Nov 24. No abstract available.

PMID:
19931523
19.

Assessment of liver fibrosis: noninvasive means.

Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, Munteanu M, Massard J, Benhamou Y, Ratziu V.

Saudi J Gastroenterol. 2008 Oct;14(4):163-73. doi: 10.4103/1319-3767.43273.

20.

Discordance between results of biomarkers of fibrosis shows that it is at least a "ménage à deux".

Munteanu M, Lebray P, Massard J, Moussalli J, Varaut A, Ngo Y, Thabut D, Imbert-Bismut F, Benhamou Y, Ratziu V, Poynard T.

Gastroenterol Clin Biol. 2009 Feb;33(2):133-4. doi: 10.1016/j.gcb.2008.12.002. Epub 2009 Feb 3. No abstract available.

Supplemental Content

Loading ...
Support Center